Haw ParHAWPF 93 3-Year RORE % is 13.03 as of Dec. 2025. GuruFocus rates HAWPF with a GF Score™ of 93/100 and a GF Value™ of $8.90. The stock has 3 warning signs investors should review. Among 937 Drug Manufacturers companies, Haw Par ranks better than 59.02% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Haw Par's 3-Year RORE % for the quarter that ended in Dec. 2025 was 13.03%.
The industry rank for Haw Par's 3-Year RORE % or its related term are showing as below:
HAWPF's 3-Year RORE % is ranked better than 59.02% of 937
companies
in the Drug Manufacturers industry
Industry Median: 3.09
vs HAWPF: 13.03
Haw Par (OTCPK:HAWPF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Haw Par 3-Year RORE % Related Terms
Haw Par 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Haw Par's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Haw Par's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Haw Par's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Haw Par (HAWPF) has a 3-Year RORE % of 13.03 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Haw Par and its competitors. According to the industry distribution chart, Haw Par ranks #384 out of 937 companies in the Drug Manufacturers industry, placing it in the top 41%.
Is Haw Par's 3-Year RORE % too high?
Haw Par's current 3-Year RORE % is 13.03. The Drug Manufacturers industry median 3-Year RORE % is 3.09. Haw Par's value of 13.03 is 321.7% above this industry median. Based on the distribution chart, Haw Par ranks #384 out of 937 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Haw Par has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Haw Par's 3-Year RORE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #384 out of 937 companies for 3-Year RORE %. This puts Haw Par in the upper half of its industry. The industry median 3-Year RORE % is 3.09. Haw Par's value of 13.03 is 321.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current 3-Year RORE % of 13.03 is 321.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current 3-Year RORE % is 13.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Haw Par (HAWPF) has a current 3-Year RORE % of 13.03. The stock's GF Value™ is $8.90, compared to a current price of $12.00 — trading 34.8% above its estimated fair value. The current 3-Year RORE % is 13.03 and 321.7% above the Drug Manufacturers industry median of 3.09. Haw Par's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Haw Par (HAWPF), the current 3-Year RORE % is 13.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.00 is trading 34.8% above its estimated GF Value™ of $8.90.
Key valuation signals for HAWPF:
3-Year RORE %: 13.03
GF Value™: $8.90 vs. price of $12.00 (34.8% above fair value)
Industry Position: 321.7% above the Drug Manufacturers median (#384 of 937)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
93GF Score
Get the complete analysis for HAWPF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
